Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioACET +0.06%34 EV-to-OCF is 0.33 as of Aug. 13, 2026, which is 89% below its 10-year median of 2.93. GuruFocus rates ACET with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,407 Biotechnology companies, Adicet Bio ranks worse than 74.63% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Adicet Bio's Enterprise Value is $-28.01 Mil.
Adicet Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-84.53 Mil. Therefore, Adicet Bio's EV-to-OCF for today is 0.33.
The historical rank and industry rank for Adicet Bio's EV-to-OCF or its related term are showing as below:
ACET'
s EV-to-OCF Range Over the Past 10 Years
Min: -21.98 Med: 2.93 Max: 4.9
Current: 0.33
During the past 8 years, the highest EV-to-OCF of Adicet Bio was 4.90. The lowest was -21.98. And the median was 2.93.
ACET's EV-to-OCF is ranked worse than 74.63% of 1407
companies
in the Biotechnology industry
Industry Median: -3.54
vs ACET: 0.33
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adicet Bio's share price for today is $8.29.
Adicet Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.450.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Adicet Bio EV-to-OCF Related Terms
Adicet Bio EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Adicet Bio's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adicet Bio's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Adicet Bio's EV-to-OCF falls into.
Adicet Bio's current Enterprise Value is $-28.01 Mil.
Adicet Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (ACET) has a EV-to-OCF of 0.33 as of Aug. 13, 2026. This is 89% below median its historical median of 2.93. According to the industry distribution chart, Adicet Bio ranks #1050 out of 1407 companies in the Biotechnology industry, placing it in the top 74.6%.
Is Adicet Bio's EV-to-OCF too high?
Adicet Bio's current EV-to-OCF of 0.33 is 89% below median its 10-year median of 2.93. Based on the distribution chart, Adicet Bio ranks #1050 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Adicet Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's EV-to-OCF compare to ATRA and PYPD?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #1050 out of 1407 companies for EV-to-OCF. This places Adicet Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Adicet Bio's current EV-to-OCF is 0.33, which is 89% below median its own 10-year median of 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (ACET) has a current EV-to-OCF of 0.33. The current EV-to-OCF is 0.33, which is 89% below median its 10-year median of 2.93. Adicet Bio's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Adicet Bio (ACET), the current EV-to-OCF is 0.33 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
34GF Score
Get the complete analysis for ACET
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACET has been successfully added to your 
